Hazlett, Burt & Watson’s United Therapeutics UTHR Stock Holding History

Hazlett, Burt & Watson’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$108K	Hold	200	–	–	0.03%	354
2026 Q1	$119K	Hold	200	–	–	0.04%	317
2025 Q4	$97K	Hold	200	–	–	0.03%	349
2025 Q3	$84K	Hold	200	–	–	0.03%	341
2025 Q2	$57K	Hold	200	–	–	0.02%	357
2025 Q1	$62K	Hold	200	–	–	0.03%	330
2024 Q4	$71K	Hold	200	–	–	0.03%	317
2024 Q3	$72K	Hold	200	–	–	0.03%	305
2024 Q2	$64K	Hold	200	–	–	0.03%	306
2024 Q1	$46K	Sell	200 -21	-10%	-$4.74K	0.03%	337
2023 Q4	$49K	Sell	221 -27	-11%	-$6.22K	0.03%	310
2023 Q3	$56K	Hold	248	–	–	0.04%	286
2023 Q2	$55K	Buy	248 +48	+24%	+$10.6K	0.04%	287
2023 Q1	$45K	Hold	200	–	–	0.04%	294
2022 Q4	$56K	Buy	+200	New	+$50.5K	0.05%	257

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Hazlett, Burt & Watson's UTHR Position: Q2 2026 in Review

Hazlett, Burt & Watson held its United Therapeutics (UTHR) position steady in Q2 2026 at 200 shares worth $108K. The position accounts for 0.03% of the portfolio, ranked #354.

Hazlett, Burt & Watson first reported a position in UTHR in Q4 2022 and has held it in 15 quarters since. The position peaked at $119K in Q1 2026. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Hazlett, Burt & Watson held 200 shares of United Therapeutics worth $108K as of Q2 2026.
Hazlett, Burt & Watson left its United Therapeutics share count unchanged in Q2 2026.
United Therapeutics made up 0.03% of Hazlett, Burt & Watson's portfolio in Q2 2026, its #354 holding.
Hazlett, Burt & Watson first reported a position in United Therapeutics in Q4 2022 and has held it in 15 quarters since.
Hazlett, Burt & Watson's United Therapeutics position peaked at $119K in Q1 2026.
881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.